



June 12, 2023

Alma Lasers, Inc.  
Attention: Jessica Rivera-Montejo  
RAQA Director  
485 Half Day Rd, Suite 100  
Buffalo Grove, IL 60089

Re: BK220668/0

Trade/Device Name: VorFat System  
Regulation Number: 21 CFR 878.5040  
Regulation Name: Suction lipoplasty system  
Regulatory Class: Class II  
Common Name: Lipoaspirate Washing System For Aesthetic Body Contouring  
Product Code: QKL  
Dated: January 14, 2022  
Received: January 14, 2022

Dear Ms. Rivera-Montejo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Steven S. Oh, PhD  
Acting Director  
Division of Cell Therapy 2  
Office of Cellular Therapy and Human Tissue  
Office of Therapeutic Products  
Center for Biologics Evaluation and Research

Enclosure: Indications for Use

**Indications for Use (CBER/OTP)**

510(k) Number: BK220668

Device Name: VorFat System

Indications for Use:

The VorFat System is intended for the closed-loop processing of lipoaspirate tissue in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue harvested with a legally marketed lipoplasty system. The device is intended for use in the following surgical specialties when the transfer of harvested adipose tissue for aesthetic body contouring is desired:

- orthopedic surgery,
- arthroscopic surgery,
- neurosurgery,
- gastrointestinal and affiliated organ surgery,
- urological surgery,
- general surgery,
- gynecological surgery,
- thoracic surgery,
- laparoscopic surgery,
- plastic and reconstructive surgery

Only legally marketed accessory items, such as syringes, should be used with the system. Any fat concentrated using this system is to be transferred back to the patient without any additional manipulation.

Prescription Use   X                        AND/OR                      Over-The-Counter Use \_\_\_\_\_

(Part 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CBER, Office of Therapeutic Products

Office Sign-Off Office of Therapeutic Products

510(k):   BK220668